文章：

小染色体维持家族在多发性骨髓瘤中的预后作用

Prognostic role of minichromosome maintenance family in multiple myeloma 

原文发布日期：2020-01-21 

英文摘要：

Multiple myeloma (MM) is a plasma cell malignancy. The minichromosome maintenance (MCM) family involve in DNA replication and is vital in limiting replication in cell cycle. The prognostic role of MCMs in MM is still unclear. We took four independent GEO datasets to analyze the relationship between the expression of MCMs and myeloma progression and survival. The expression of MCMs showed an upward trend with myeloma progression in 205 patients. High MCM2/3/4/6/8 expression was associated with both poor EFS and OS (all p < 0.050). Multivariate analysis demonstrated that high MCM2 expression, B2M, and LDH were independent risk factors. Moreover, the combination of MCM2/B2M and MCM2/LDH was a better tool in prognostication. In conclusion, high MCM2 expression is an independent adverse prognostic factor and could be used as a prognostic biomarker in MM. 

摘要翻译： 

多发性骨髓瘤（MM）是一种浆细胞恶性肿瘤。微小染色体维持蛋白（MCM）家族参与DNA复制过程，并在限制细胞周期复制中起关键作用。目前MCM家族在MM中的预后作用尚不明确。我们通过四个独立的GEO数据集分析了MCM表达与骨髓瘤进展及生存预后的关系。在205例患者中，MCM表达水平随疾病进展呈现上升趋势。高表达的MCM2/3/4/6/8与较差的无事件生存期（EFS）和总生存期（OS）均显著相关（所有p值<0.050）。多因素分析显示，高MCM2表达、β2微球蛋白（B2M）和乳酸脱氢酶（LDH）均为独立危险因素。此外，MCM2/B2M和MCM2/LDH联合检测能提供更准确的预后预测。综上所述，MCM2高表达是一个独立的不良预后因素，可作为多发性骨髓瘤的预后生物标志物。

原文链接：

Prognostic role of minichromosome maintenance family in multiple myeloma